Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luís Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
The Lancet (2019) Vol. 394, Iss. 10212, pp. 1929-1939
Closed Access | Times Cited: 1696

Showing 1-25 of 1696 citing articles:

Lung cancer
Alesha Thai, Benjamin Solomon, Lecia V. Sequist, et al.
The Lancet (2021) Vol. 398, Iss. 10299, pp. 535-554
Closed Access | Times Cited: 1654
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 759-771
Closed Access | Times Cited: 1073
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 345-362
Closed Access | Times Cited: 1051
Small-cell lung cancer
Charles M. Rudin, Élisabeth Brambilla, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 996
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 835
The rediscovery of platinum-based cancer therapy
Sven Rottenberg, Carmen A. Widmer, Paola Perego
Nature reviews. Cancer (2020) Vol. 21, Iss. 1, pp. 37-50
Closed Access | Times Cited: 687
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, et al.
Cancer Cell (2021) Vol. 39, Iss. 3, pp. 346-360.e7
Open Access | Times Cited: 678
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, et al.
NEJM Evidence (2022) Vol. 1, Iss. 8
Closed Access | Times Cited: 653
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin, Mark M. Awad, Alejandro Navarro, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 21, pp. 2369-2379
Open Access | Times Cited: 582
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen V. Liu, Martin Reck, Aaron S. Mansfield, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 6, pp. 619-630
Open Access | Times Cited: 558
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 544
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, et al.
The Lancet Oncology (2020) Vol. 22, Iss. 1, pp. 51-65
Closed Access | Times Cited: 523
Lung cancer immunotherapy: progress, pitfalls, and promises
Aritraa Lahiri, Avik Maji, Pravin D. Potdar, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 520
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey, Baolin Zhang
The AAPS Journal (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 508
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 497
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 23, pp. 2145-2158
Open Access | Times Cited: 472
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 430
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Anne‐Marie C. Dingemans, Martin Früh, Andrea Ardizzoni, et al.
Annals of Oncology (2021) Vol. 32, Iss. 7, pp. 839-853
Open Access | Times Cited: 385
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Émilie Le Rhun, Matthias Gückenberger, Marion Smits, et al.
Annals of Oncology (2021) Vol. 32, Iss. 11, pp. 1332-1347
Open Access | Times Cited: 371
Antiemetics: ASCO Guideline Update
Paul J. Hesketh, Mark G. Kris, Ethan Basch, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 24, pp. 2782-2797
Closed Access | Times Cited: 327
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, et al.
Journal of Thoracic Oncology (2019) Vol. 15, Iss. 4, pp. 618-627
Open Access | Times Cited: 317
Paradigms on Immunotherapy Combinations with Chemotherapy
Diego Salas‐Benito, José Luis Pérez‐Gracia, Mariano Ponz‐Sarvisé, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1353-1367
Open Access | Times Cited: 310
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor Ganti, Billy W. Loo, M. Bassetti, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 12, pp. 1441-1464
Open Access | Times Cited: 305
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lü, Junye Wang, Yongqian Shu, et al.
BMJ (2022), pp. e068714-e068714
Open Access | Times Cited: 289
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Joseph M. Chan, Álvaro Quintanal-Villalonga, Vianne R. Gao, et al.
Cancer Cell (2021) Vol. 39, Iss. 11, pp. 1479-1496.e18
Open Access | Times Cited: 280
Page 1 - Next Page

Scroll to top